OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Leath on the Results of the GOG 240 Trial in Advanced Cervical Cancer

November 7th 2019

Charles A. Leath III MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses results of the phase III GOG 240 trial in advanced cervical cancer.

Dr. Schwartzberg on the Use of Therapeutic Biosimilars in Breast Cancer

November 7th 2019

Lee S. Schwartzberg, MD, FACP, chief medical officer, OneOncology, chief and professor of medicine, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, and executive director, West Cancer Center, discusses the use of therapeutic biosimilars in breast cancer.

Dr. Fowler on Considerations for Cytoreductive Surgery in Ovarian Cancer

November 7th 2019

Jeffrey M. Fowler, MD, discusses factors used to determine whether a patient with advanced ovarian cancer is eligible for primary cytoreductive surgery.

Dr. Weber on Biomarker Data From CheckMate-238 for Melanoma

November 7th 2019

Jeffrey S. Weber, MD, PhD, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.

Dr. Rajdev on the Difference Between Cancers and Carcinomas in NETs

November 6th 2019

Lakshmi N. Rajdev, MD, an associate professor, Department of Medicine (Oncology), at Albert Einstein College of Medicine, Montefiore Medical Center, discusses the difference between cancers and carcinomas in neuroendocrine tumors (NETs).

Dr. Kim Discusses Data From the IMpower150 Trial in Nonsquamous NSCLC

November 6th 2019

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses data from the phase III IMpower150 trial in advanced nonsquamous non–small cell lung cancer (NSCLC).

Dr. Zain on Targets Under Investigation in T-Cell Lymphomas

November 6th 2019

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses targets that are under investigation in T-cell lymphomas.

Dr. Mailankody on CASSIOPEIA Results in Newly Diagnosed Multiple Myeloma

November 6th 2019

Sham Mailankody, MBBS, discusses results of the CASSIOPEIA trial in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Dr. Hassan on FLAURA Trial Results in EGFR-Mutant NSCLC

November 6th 2019

Khaled A. Hassan, MD, MS, discusses the results of the FLAURA trial, which compared osimertinib with first-generation TKIs in patients with EGFR-mutant metastatic non–small cell lung cancer.

Dr. Wozniak on Sequencing Immunotherapy in Lung Cancer

November 5th 2019

Antoinette Wozniak, MD, FACP, FASCO, discusses sequencing with immunotherapy and chemoradiation in select patients with stage III lung cancer.

Dr. Lawrenz on Hypofractionated Radiotherapy in Soft Tissue Sarcoma

November 5th 2019

Joshua M. Lawrenz, MD, discusses a study looking at hypofractionated radiotherapy in soft tissue sarcoma.

Dr. O'Malley on Toxicity Profiles of PARP Inhibitors in Ovarian Cancer

November 5th 2019

David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

Dr. Backes on Next Steps for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

November 5th 2019

Floor J. Backes, MD, discusses the next steps regarding a phase I trial investigating lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Dr. Long on Including Patients With Melanoma Who Have Brain Mets on Clinical Trials

November 5th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses how to efficiently enroll patients with melanoma who have brain metastases in clinical trials.

Dr. Vidal on Increasing Access to HER2-Targeted Therapy With Biosimilars

November 4th 2019

Gregory Vidal, MD, PhD, explains how biosimilars could increase access to HER2-targeted therapy.

Dr. Ho on Frontline Treatment Regimens in mRCC

November 4th 2019

Thai H. Ho, MD, PhD, discusses frontline treatment regimens in metastatic renal cell carcinoma.

Dr. Meric-Bernstam on the Safety and Efficacy of ZW25 in HER2-Expressing Solid Tumors

November 4th 2019

Funda Meric-Bernstam, MD, discusses the safety and efficacy of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumors.

Dr. Kerrigan on Sequencing Challenges in ALK+ NSCLC

November 4th 2019

Katie Kerrigan, MD, discusses sequencing challenges in the treatment of patients with ALK-positive non–small cell lung cancer.

Dr. Giralt on Transplant Eligibility Criteria in Multiple Myeloma

November 2nd 2019

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses transplant eligibility criteria in multiple myeloma.

Dr. Wang on Addition of Acalabrutinib to Bendamustine/Rituximab in MCL

November 2nd 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the addition of acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).